Lorazepam is a benzodiazepine, and benzodiazepines are one of the standard drug classes screened on most panel tests, so you would expect a straightforward “yes.” In practice, though, lorazepam is one of the most commonly missed benzodiazepines on standard urine drug screens. The reason has to do with how the body processes the drug and how the most widely used screening tests actually work. Whether your lorazepam use registers as positive depends heavily on the type of test, the laboratory’s methods, and the dose you took.
Why Standard Urine Tests Often Miss Lorazepam
Most workplace, clinical, and forensic drug screens start with an immunoassay, a quick chemistry-based test that uses antibodies designed to react with a target substance. The benzodiazepine immunoassays used in the vast majority of labs were originally designed around older benzodiazepines like diazepam and its metabolites. Those drugs break down in the body into compounds that the test antibodies recognize well. Lorazepam takes a different metabolic path. Your body converts it almost entirely into a compound called lorazepam glucuronide before excreting it in urine, and this glucuronidated form barely registers on the antibodies used in standard screens.
A recent clinical case report examined manufacturer data for a widely used commercial benzodiazepine immunoassay and found that while the test lists 62% cross-reactivity with lorazepam itself, the cross-reactivity with lorazepam glucuronide, the form that actually appears in urine, is just 0.50%. The authors calculated that it would take a concentration of roughly 20,000 micrograms per liter of lorazepam glucuronide to trigger a positive result, a level so high it would be dangerous or potentially fatal.1The Primary Care Companion for CNS Disorders. Is My Patient Diverting Their Lorazepam? In other words, someone taking a normal prescribed dose of lorazepam can easily produce a negative result on a standard urine drug screen, even though the drug is genuinely present in their system.
This was demonstrated directly in a controlled study where four healthy volunteers each took a single 1-milligram lorazepam tablet and then provided urine samples at regular intervals over 48 hours. Using a standard 200 ng/mL cutoff, none of the four commercial immunoassays tested produced a single positive result from any of the untreated urine samples.2PubMed. Comparison of four immunoassays for the detection of lorazepam in urine Every sample came back negative, despite lorazepam and its metabolite being present. Lorazepam is not the only benzodiazepine with this problem. Other glucuronidated benzodiazepines can also cross-react poorly with standard immunoassays, leading to false negatives.3PubMed Central. Comparison of two highly sensitive benzodiazepine immunoassay lab developed tests for urine drug testing in clinical specimens
How Labs Can Catch What Screening Tests Miss
The problem is not that lorazepam is undetectable. It is that the fastest and cheapest screening method happens to be nearly blind to it. Labs that know to look for lorazepam have a few options that dramatically improve detection.
The most direct fix is enzymatic hydrolysis, a pre-treatment step where the lab adds an enzyme to the urine sample that breaks lorazepam glucuronide back into free lorazepam before running the immunoassay. In that same four-volunteer study, when samples were pre-treated with a beta-glucuronidase enzyme, one of the four immunoassays went from zero positive results to 35 out of 48 samples testing positive.2PubMed. Comparison of four immunoassays for the detection of lorazepam in urine That is a massive swing, from complete invisibility to detection in nearly three-quarters of samples, all from the same urine. Some labs now use “high sensitivity” assays that incorporate glucuronidase directly into the test reagents, specifically to catch benzodiazepines like lorazepam that are excreted primarily in glucuronidated form.3PubMed Central. Comparison of two highly sensitive benzodiazepine immunoassay lab developed tests for urine drug testing in clinical specimens
There is a practical wrinkle with the hydrolysis step, though. Research on enzymatic treatment conditions has found that lorazepam shows some instability when exposed to higher temperatures during the hydrolysis process, declining by up to about 20% when incubated at 55°C for 60 minutes. Using enzymes that work at room temperature and require shorter incubation times reduces both preparation time and the risk of losing some of the drug during sample processing.4PubMed Central. Exploring Enzymatic Hydrolysis of Urine Samples for Investigation of Drugs Associated with Drug-Facilitated Sexual Assault
Confirmatory testing, which labs turn to when they need a definitive answer, uses entirely different technology. Techniques like liquid chromatography-tandem mass spectrometry (usually written as LC-MS/MS) or gas chromatography-mass spectrometry can identify lorazepam and its metabolites directly, regardless of the glucuronide problem. If a confirmatory test is ordered specifically for lorazepam, it will find it if it is there. The catch is that confirmatory testing is more expensive and slower, so it is typically reserved for cases where the screening result is disputed, a specific drug needs to be identified, or the clinical situation demands certainty.
What About Oral Fluid and Hair Tests
Urine is the most common sample type for drug testing, but it is not the only one. Oral fluid (saliva) testing has become more common in roadside checks, workplace programs, and some clinical settings. For lorazepam, the detection window in saliva is considerably shorter than in urine. One study found that oral fluid tested positive for lorazepam for about 8 hours after a dose, with concentrations dropping to very low levels (around 0.7 ng/mL at the end of that window).5PubMed. Windows of detection of lorazepam in urine, oral fluid and hair, with a special focus on drug-facilitated crimes That is a fairly narrow window compared to what you might expect from a drug whose sedative effects can linger longer than 8 hours in some people.
Hair testing offers the longest detection window of any sample type, potentially revealing drug use over weeks or months. However, hair testing for benzodiazepines, including lorazepam, is generally less sensitive than it is for stimulants or opioids, and it is primarily used in forensic or legal contexts rather than standard employment or clinical drug screens. If you are being tested through a standard workplace or clinical program, you are almost certainly providing a urine sample, and the immunoassay sensitivity issue described above is your primary concern.
How Long Lorazepam Stays in Your System
Lorazepam has an elimination half-life of roughly 10 to 20 hours in most adults, meaning it takes your body that long to clear half of a dose. As a rule of thumb, it takes about five half-lives for a drug to be effectively eliminated from your system. For lorazepam, that puts the clearance window at roughly two to four days after a single dose for most people, though this varies with age, liver function, body composition, and dose size. Older adults and people with liver impairment tend to metabolize the drug more slowly.
The practical catch, as discussed above, is that “still in your system” and “detectable on a drug test” are not the same thing when it comes to lorazepam. Someone who took a single low dose might have lorazepam glucuronide in their urine for two or three days, but a standard immunoassay could return a negative result the entire time. Someone taking higher or more frequent doses has a better chance of producing enough metabolite to trigger a positive screen, but even chronic therapeutic use does not guarantee a positive on every test. This is why clinicians sometimes see patients with a legitimate prescription for lorazepam whose routine urine screens consistently come back negative for benzodiazepines, which can raise unfounded concerns about whether the patient is actually taking their medication or potentially selling it.1The Primary Care Companion for CNS Disorders. Is My Patient Diverting Their Lorazepam?
False Positives for Benzodiazepines
While lorazepam’s bigger problem is false negatives, the broader benzodiazepine immunoassay has a well-documented false positive problem as well. Several medications that have nothing to do with benzodiazepines can trip the screening test.
Sertraline, a widely prescribed antidepressant (brand name Zoloft), has been linked to false-positive benzodiazepine screens. A two-year retrospective analysis at one institution reviewed 522 records with positive benzodiazepine screens and found that 160 turned out to be false positives when checked with confirmatory mass spectrometry testing. Of the false positives that could not be explained by a concurrent benzodiazepine prescription, 26 were associated with sertraline use, suggesting the antidepressant was triggering the false result.6PubMed Central. False-Positive Urine Screening for Benzodiazepines: An Association with Sertraline?: A Two-year Retrospective Chart Analysis
Oxaprozin, a nonsteroidal anti-inflammatory drug (NSAID), is another well-known culprit. When researchers tested urine from 12 volunteers taking therapeutic doses of oxaprozin, every single sample triggered a positive benzodiazepine result on multiple immunoassay platforms. All 36 urine specimens came back positive on two of the three assays tested, and 35 of 36 were positive on the third.7PubMed. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine If you are taking oxaprozin and face a drug screen, a false positive for benzodiazepines is almost certain with a standard immunoassay.
Other substances reported to cause false-positive benzodiazepine screens include certain other NSAIDs and the sleep aid efavirenz. The consistent lesson is that a positive immunoassay screen for benzodiazepines should never be treated as definitive without confirmatory testing. This is standard laboratory practice, but in some clinical or employment settings, a positive screen can trigger consequences before the confirmatory result comes back.
What Workplace and Legal Drug Tests Actually Screen For
The standard federally regulated workplace drug test in the United States, sometimes called a “5-panel” test, screens for amphetamines, cannabinoids, cocaine, opiates, and PCP. Benzodiazepines are not on the standard federal panel. However, many employers, particularly in healthcare, transportation, and safety-sensitive industries, use expanded panels (7-panel, 10-panel, 12-panel) that do include benzodiazepines. If you have a legitimate prescription for lorazepam and you are subject to an expanded panel, the typical process is to disclose the prescription to the Medical Review Officer (MRO), who can verify it and report the result as negative.
Even on expanded panels, the false-negative problem persists. A study examining post-accident and random workplace urine drug tests found that among positive benzodiazepine screening results, only about 30% of post-accident screens and roughly 21% of random screens were confirmed positive by follow-up laboratory testing.8PubMed Central. Benzodiazepines and workplace safety: an examination of postaccident urine drug tests That means the majority of initial positive screens in this workplace sample turned out to be wrong. This high rate of unconfirmed positives reflects both the false-positive problem from cross-reacting substances and the general imprecision of immunoassay screening for the benzodiazepine class.
If you are prescribed lorazepam and worried about a workplace test, the realistic scenario is paradoxical. You are more likely to test negative despite taking the drug than to test positive because of it. The bigger practical risk might be a false positive from something else you are taking. In either case, confirmatory testing and MRO review exist to sort out the truth.
When Your Doctor Orders a Drug Test
Clinical drug testing, the kind a doctor orders to monitor a patient’s medication use, operates differently from workplace testing. Physicians prescribing benzodiazepines often use urine drug screens to verify that patients are taking their medications as prescribed and not using additional substances. The lorazepam detection gap creates real problems here. A patient faithfully taking their lorazepam can produce a negative urine screen, and the doctor, unaware of the immunoassay’s blind spot, might conclude the patient is not taking the medication or is diverting it (selling or giving it away).1The Primary Care Companion for CNS Disorders. Is My Patient Diverting Their Lorazepam?
This scenario is more common than most patients or doctors realize. If your provider prescribes lorazepam and relies on standard urine drug screens for monitoring, it is worth having a direct conversation about the test’s limitations. A provider who understands the glucuronide cross-reactivity issue can either order a high-sensitivity assay, request specific confirmatory testing for lorazepam, or simply interpret the negative screen in context rather than jumping to conclusions about adherence.
Designer Benzodiazepines and Evolving Testing Challenges
The drug testing landscape has become more complicated with the emergence of designer benzodiazepines, novel compounds that are chemically similar to prescription benzodiazepines but are not approved by regulatory agencies. These substances, which include compounds like flualprazolam, flubromazolam, clonazolam, and etizolam, sometimes appear in counterfeit prescription pills or are sold directly through illicit markets.
A study that investigated apparent false-positive benzodiazepine screening results, cases where the screen was positive but confirmatory testing for standard prescription benzodiazepines found nothing, revealed that designer benzodiazepines were the culprit in the vast majority of cases. Using advanced analytical techniques, researchers detected at least one non-approved benzodiazepine in 30 out of 35 specimens that had initially been flagged as false positives. In 13 of those specimens, two or three different designer benzodiazepines were present simultaneously.9Oxford Academic (Journal of Analytical Toxicology). Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS
Standard confirmatory panels, which are designed to detect known prescription benzodiazepines, do not typically include these designer compounds. So a person using a designer benzodiazepine might screen positive on the initial immunoassay (because the novel compound cross-reacts with the antibodies) but then appear negative on the standard confirmatory test (because the confirmatory panel does not look for that particular substance). The result gets labeled a false positive when it is really a true positive for a substance the lab was not expecting. This matters for clinical monitoring, forensic investigations, and understanding the actual scope of benzodiazepine use in populations being tested. As the illicit benzodiazepine market continues to evolve, testing laboratories are slowly expanding their confirmatory panels, but the technology tends to lag behind the chemistry.
Home Drug Tests and Point-of-Care Kits
If you have ever bought a home drug test kit at a pharmacy or been tested with a rapid point-of-care cup at a clinic, the technology in those devices is the same basic immunoassay that professional labs use for initial screening. The lorazepam problem applies here just as much, if not more. Home kits and rapid cups do not include a hydrolysis step and cannot perform confirmatory mass spectrometry. A negative result for benzodiazepines on a home test after taking lorazepam does not mean the drug is out of your system. It means the test cannot see it.
This has practical implications for people trying to gauge their own test readiness, parents testing a family member, or clinics using rapid cups as a first-line tool. The bottom-line reality is that point-of-care immunoassays are useful for catching many benzodiazepines, particularly the older ones like diazepam and chlordiazepoxide, but they are unreliable for lorazepam at therapeutic doses. Research comparing four immunoassays found that without enzymatic pre-treatment, not a single one could produce a positive for lorazepam at normal prescribed levels.2PubMed. Comparison of four immunoassays for the detection of lorazepam in urine If accurate detection of lorazepam is the goal, a lab-based test with either hydrolysis or direct mass spectrometry is the only reliable route.